NCT03157830View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

CompletedOBSERVATIONAL
Enrollment

43

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

January 28, 2022

Study Completion Date

June 6, 2022

Conditions
Relapsing Remitting Multiple Sclerosis
Trial Locations (5)

97225

Providence MS Center, Portland

98122

Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle

99208

Providence Multiple Sclerosis Center, Spokane

99352

Kadlec Neuroscience Center, Richland

07039

RWJBarnabas Health, Livingston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Providence Health & Services

OTHER

NCT03157830 - Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab | Biotech Hunter | Biotech Hunter